Navigation Links
Questcor Pharmaceuticals Responds to Questions From Investor Blog
Date:1/16/2012

roved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All such statements have been made pursuant to the Private Securities Litigation Reform Act of 1995, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "if," "should," "forecasts," "intends," "exploring," "expects," "plans," "appears," "grows," "believes," "estimates," "predicts," "potential," "continue" or "trends" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our nets sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient complianc
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Questcor Pharmaceuticals Issues Statement
2. Questcor Pharmaceuticals Reports Strong Finish to 2011
3. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
4. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
5. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
6. Questcor Reports Third Quarter Financial Results
7. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
8. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
9. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
10. Questcor Provides Updated New Paid Prescription Trends
11. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... operations in China and ... release financial results for the second quarter of 2014 after ... 2014 (which will be Thursday morning, August 14, 2014 Shanghai ... relations section of the Company,s website at http://www.wuxiapptec.com ...
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Nov. 1, 2011 Lexicon Pharmaceuticals, Inc. ... on discovering and developing breakthrough treatments for human disease, ... results for the three and nine months ended September ... studies of LX4211 and LX1032 have provided further validation ...
... Corporation (NASDAQ: VOLC ), a leading developer and ... to enhance the treatment of coronary and peripheral artery disease, ... increased 18 percent versus the third quarter of 2010. ... revenues of $85.8 million versus revenues of $72.9 million in ...
Cached Medicine Technology:Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 2Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 3Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 4Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 5Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 6Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 7Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 8Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 2Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 3Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 4Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 5Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 6
(Date:7/22/2014)... July 22, 2014 Get Real ... Immune Deficiency Foundation (IDF) to provide their ... that will allow them to electronically track their symptoms, ... their illnesses. It will also allow those patients and ... consent to have their data shared with the ...
(Date:7/22/2014)... 22, 2014 JumpSoft, Inc., a ... automated recovery at the application level, today released ... to application-centric management. , Based on ... the report provides insights, context and depth regarding ... application and system uptime. London, Ink, a B2B ...
(Date:7/22/2014)... Recently, MyDressCity.com has excitedly launched a promotion for ... all people can get a discount, up to 60% off, ... the new range; all the new items are of top ... Quinceanera gowns for worldwide clients. Our dress specialists are always ... of MyDressCity.com, “Our Quinceanera dresses are selling well in the ...
(Date:7/22/2014)... July 22, 2014 BlackBox Biometrics, Inc. ... Gauge™ System with advancements including a new ... gauges represent a functional revision of the already robust ... capture complex data on blast events by recording a ... The extreme changes in overpressure that accompany a blast ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 "The Big Secrets: ... is one of the most important books young people can read. ... It will murder some of the “truths” people have been living ... what will the new truths be? From sex to death, this ... age 16 to 21, and it tells it like it is. ...
Breaking Medicine News(10 mins):Health News:Get Real Health to Partner with Immune Deficiency Foundation 2Health News:Get Real Health to Partner with Immune Deficiency Foundation 3Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 2Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 3Health News:Beautiful Dama Dresses Now Released By Popular Online Supplier MyDressCity.com 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3Health News:Strategic Book Publishing & Rights Agency Announces the Release of its Newest Title, “The Big Secrets: Ten Things Every Young Person Should Know About and Why” 2
... number of HIV cases in Africa as of last ... from the United Nations //.The World Health Organization has ... AIDS in Africa. ,The WHO has ... in healthcare in Africa could be used to give ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... replaced by a pill according to European researchers. The ... of the Grazax allergen tablet.// Hay fever and other ... ,Allergies are a result of the immune system reacting ... ,Immunotherapy is supposed to enhance tolerance of ...
... of people admitted into hospitals with diabetic related issues is ... of Health and Welfare.// ,The author of the report, ... and 2004, hospital admissions for diabetes increased by 20 per ... more people are being diagnosed with diabetes, it is increasing ...
... have found that a glass of orange juice every day ... citrus juices like lemonade. // ,The study that is ... 26 issue of the Clinical Journal of the American Society ... that all citrus fruit juices could help prevent the formation ...
... Australia are conducting a study involving 300 pairs of older ... ,'Even though we have twins that are identical, ... Sachdev said. 'By studying twins, we will be able to ... and which are environmental.' ,Prof Sachdev said that time ...
Cached Medicine News:Health News:A Glass of Orange Juice To Keep Recurrence Of Kidney Stones At Bay 2
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
The latest wave in punctum plugs! Unique design featureing reservoir indentations to reduce foreign body sensation. Elast™ - a proprietary formulated, hight performance Liquid Silicon Rubber ...
... Attain Prevail's steerable tip, along with various ... obtain the curve you need, when you ... visualization of the cardiac venous anatomy, adjust ... - Adjust curve and reach by ...
... Attain™ Deflectable Catheter - designed to be ... single catheter. Steerablility - Create a variety ... a single, steerable guide catheter. Lock the ... to address each patient's unique anatomy during ...
Medicine Products: